BNTCBenitec Biopharma Inc.
$8.62-46% 1Y
$8.62
$8.0952 weeks$16.52
BNTC as reported
Benitec Biopharma Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied
- Net income
- −$46M
Net income · +20% year on year · trailing twelve months to Q4 2026
- EPS
- −$0.98
EPS · −4.9% year on year · trailing twelve months to Q4 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q3 2025 · 5 quarters behind |
| Net income | −$46M | +20% | Q4 2026 |
| EPS | −$0.98 | −4.9% | Q4 2026 |
| Operating margin | −225710% | n/a | Q4 2021 · 20 quarters behind |
| Net margin | −230298% | n/a | Q4 2021 · 20 quarters behind |
| ROE | −29% | n/a | Q4 2026 |
| ROA | −28% | n/a | Q4 2026 |
| Free cash flow | −$16M | n/a | Q4 2022 · 16 quarters behind |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Benitec Biopharma Inc. (BNTC) · Revenue and profitRevenue and profitBenitec Biopharma Inc. (BNTC)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
